Effect of Intravenous Amantadine Sulphate on Disorders of Consciousness

Summary

Double-blind, placebo-controlled, crossover ("within subjects") study with an A-B-A-B treatment scheme to investigate the neuromodulatory effects of intravenous amantadine sulphate at a single daily dose of 200 mg in patients with disorders of consciousness (unresponsive wakefulness syndrome and minimally conscious state) by integrating traditional neurobehavioral assessment with spectral analysis of electrocortical activity derived from 64-channel electroencephalography (EEG) recordings.

Timeline

Start

2018-09-15

Primary completion

2024-01-10

Completion

2024-09-30

Drugs

Indications